Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: 5-Azacytidine
Drug: Lenalidomide

First Posted Date: 2009-12-24

Last Posted Date: 2017-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 94

Registration Number: NCT01038635

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

Phase 2

Completed

Conditions: Myeloma

Interventions: Drug: Topotecan
Drug: Cyclophosphamide
Drug: Melphalan
Other: Peripheral Blood Stem Cells

First Posted Date: 2009-12-24

Last Posted Date: 2018-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT01039025

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

M. D. Anderson Symptom Inventory - Ovarian Cancer

Completed

Conditions: Ovarian Cancer

Interventions: Behavioral: Interview
Behavioral: Survey

First Posted Date: 2009-12-23

Last Posted Date: 2018-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 158

Registration Number: NCT01037751

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Lyndon B. Johnson General Hospital, Houston, Texas, United States

Chlorhexidine Gel Therapy for Cariogenic Oral Microflora

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: 1% Chlorhexidine Gluconate Gel
Behavioral: Surveys

First Posted Date: 2009-12-21

Last Posted Date: 2016-02-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT01036412

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Panitumumab
Drug: Nab-paclitaxel
Drug: Carboplatin
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2009-12-21

Last Posted Date: 2023-03-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT01036087

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)

Not Applicable

Conditions: Cardiac Toxicity
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Other: Laboratory Biomarker Analysis
Behavioral: Questionnaires

First Posted Date: 2009-12-15

Last Posted Date: 2019-05-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 597

Registration Number: NCT01032278

Locations: 🇺🇸
Lyndon B. Johnson General Hospital (LBJ), Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients

Completed

Conditions: Gynecologic Cancer

Interventions: Behavioral: Surveys

First Posted Date: 2009-12-14

Last Posted Date: 2013-05-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 160

Registration Number: NCT01031602

Locations: 🇺🇸
Lyndon B. Johnson (LBJ) General Hosptial, Houston, Texas, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Palonosetron
Drug: Ondansetron

First Posted Date: 2009-12-14

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT01031498

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Comparison of PEM Uptake Value (PUV) and Standardized Uptake Value (SUV) in Patients With Malignancies of the Breast

Completed

Conditions: Breast Cancer

First Posted Date: 2009-12-14

Last Posted Date: 2015-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT01031238

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Detection of Cervical Lymph Node Metastases With a High-Resolution Positron Emission Tomography (PET) Imaging System

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2009-12-11

Last Posted Date: 2014-05-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01030497

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy